An interventional study of Educational Webinar and Resources in Evaluation Studies, Implementation Research and Decision Aid, sponsored by Unity Health Toronto. Completed at 1 site in Canada. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Unity Health Toronto · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.
Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 457th largest by enrollment of the 787 interventional ones that give a count, is one of 41 that started in 2018, is one of 204 with no phase, and was the 590th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Canada, United States
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Novartis Pharmaceuticals · Sites in Canada, United States, Australia and 1 more country
Ages 18+
British Columbia Cancer Agency · Sites in Canada
Ages 40+ · Women only
Novartis Pharmaceuticals · Sites in Canada, United States, France and 6 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
907 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 129 · Phase 2 246 · Phase 3 255 · Phase 4 25
First in 1988; this study’s year is marked. 41 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 155 across the 787 interventional studies, 199 across the 110 observational. Of the 575 that completed or were terminated, 230 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
374 of 907 have an industry lead sponsor. The 10 most frequent:
Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Unity Health Toronto has 4 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Breast Neoplasms with a site in Canada that are under way reach primary completion within a year, 14 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
Add all 61 to your calendar (.ics) → With an account.
Among the 907 studies in Breast Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Begin Exploring Fertility Options, Risks and Expectations (BEFORE) decision aid was created to support fertility discussions and decision-making for young breast cancer patients in Canada. While decision aids are valuable as an adjunct to consultations with health care providers, successful implementation in clinical settings following development remains low.
This goal of this study was to evaluate the effectiveness of an educational intervention (a one-hour webinar targeted to oncology nurses introducing the BEFORE decision aid, and posters and handouts in clinical settings) on health care provider recommendations of fertility tools to young breast cancer patients. The main question aims to answer:
- What is the proportion of patients who were planning or were unsure about having future children who reported their health care provider recommended fertility tools following the intervention?
Data from a fertility questionnaire that young breast cancer patients are completing as part of an ongoing prospective cohort study in Canada will be used to answer the main question.
A pragmatic stepped wedge cluster randomized trial was completed by sequentially administering an educational intervention and implementing the BEFORE decision aid in 19 centres across Canada that were recruiting young breast cancer patients for the Reducing the bUrden of Breast cancer in Young women (RUBY) Study (https://www.rubystudy.ca/Home).
There were 19 participating RUBY centres grouped into 12 clusters (1 to 3 centres per cluster). The intervention was sequentially rolled out to all centres between March 2019 and January 2020. Two clusters moved from the control period to the intervention period every 7 weeks (called a 'step'). There was 6 steps plus a baseline step during the study period. At the end of the study period all clusters (i.e., participating RUBY sites) received the intervention. The time-point of when the clusters were switched from control to intervention and the two clusters that received the intervention together was randomized.
Eligible participants included those who indicated they were planning or were unsure about having future children and were enrolled in the RUBY study during the study period. The data collection includes obtaining secondary data collected as part of the RUBY study. Specifically, demographic data and data from a fertility questionnaire completed at 3-months following enrollment in the RUBY study was used to determine the primary outcome.
The primary outcome was the number of patients reporting that their health care provider recommended fertility tools. We hypothesized that following the intervention a 20% difference would be observed, from 10% in the control period to 30% in the intervention period, in the number of patients who report that someone in their care team recommended a fertility tool.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Eligible patients included those enrolled in the RUBY study during the study period who indicated on a 3-month fertility questionnaire that they were unsure or planning on having one of more (additional) children in the future.
The RUBY study eligibility criteria includes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The educational intervention included two aspects: 1. A one hour webinar was conducted with health care providers. The target audience was oncology nurses but any health care provider that discussed fertility with breast cancer patients was able to participate. The webinar was interactive and included an overview of oncofertility, explained how treatment can cause infertility, and provided information on the fertility preservation options available before and after treatment, approximate cost of fertility preservation in Canada, fertility resources, and how to overcome barriers in oncofertility. The webinar also provided an overview on the BEFORE decision aid development and content, along with training on use of the tool in clinical settings. 2. We advertised the availability of the BEFORE decision aid through posters and handouts in clinic areas at each of the centres.
Behavioral: Educational Webinar and Resources
Participants in this group did not receive the educational webinar or resources intervention.
Educational webinar and resources on oncofertility and the BEFORE decision aid
Patient-reported Outcome Questionnaire - Fertility Preservation Questionnaire
The number of patients reporting that their health care provider recommended fertility tools
Time frame: 3 months from date of randomization
All enrolled RUBY study participants at 19 centres across Canada who indicated they were planning or unsure about having future children. Overall study period was July 30, 2018 - November 11, 2018 (baseline step) and March 18, 2019 - March 2, 2020 (intervention period).
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 44 | 0 |
| Completed | 44 | 0 |
| Not completed | 0 | 0 |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 9 | NA |
| Completed | 9 | NA |
| Not completed | 0 | NA |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 10 | 5 |
| Completed | 10 | 5 |
| Not completed | 0 | 0 |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 2 | 3 |
| Completed | 2 | 3 |
| Not completed | 0 | 0 |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 2 | 3 |
| Completed | 2 | 3 |
| Not completed | 0 | 0 |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 1 | 10 |
| Completed | 1 | 10 |
| Not completed | 0 | 0 |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 0 | 15 |
| Completed | 0 | 15 |
| Not completed | 0 | 0 |
| Milestone | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Started | 0 | 12 |
| Completed | 0 | 12 |
| Not completed | 0 | 0 |
The number of patients reporting that their health care provider recommended fertility tools
| Participants | No Educational Webinar and Resources (No EWR) | Educational Webinar and Resources (EWR) |
|---|---|---|
| Patient-reported Outcome Questionnaire - Fertility Preservation Questionnaire | 14 | 16 |
Collected over NA - AEs were not monitored/assessed. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| No Educational Webinar and Resources (No EWR) | — | — | — |
| Educational Webinar and Resources (EWR) | — | — | — |
| Age, Categorical(Participants) | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 68 | 48 | 116 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) | Total |
|---|---|---|---|
| Female | 68 | 48 | 116 |
| Male | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | No Educational Webinar and Resources (EWR) | Educational Webinar and Resources (EWR) | Total |
|---|---|---|---|
| Canada | 68 | 48 | 116 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Mar 2020, 19 months.
Results were first posted in Oct 2026, 6 years 7 months after primary completion.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 19 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Sep 2018 → Jul 2018, primary completion Oct 2019 → Mar 2020 and completion Dec 2019 → Mar 2020.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.